Notice of Intent to Sole Source – Illumina
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the Department of Laboratory Medicine (DLM) at the Clinical Center (CC), has issued a Notice of Intent to Sole Source for a maintenance agreement for the Illumina NovaSeq X plus sequencer. The intended awardee is Illumina, Inc., located in San Diego, CA. This acquisition is for services at Bethesda, MD. Responses from interested parties are due by May 5, 2026, at 11am EST.
Scope of Work
This acquisition is for a maintenance agreement for the Illumina NovaSeq X plus sequencer. The instrument is manufactured and serviced exclusively by Illumina, Inc., making continuation of maintenance from the original manufacturer necessary.
Contract & Timeline
- Type: Special Notice (Notice of Intent to Sole Source)
- Intended Award Type: Fixed-price purchase order
- Intended Awardee: Illumina, Inc.
- Justification: Sole source due to Illumina being the original manufacturer and servicer, with maintenance required from them.
- FAR Procedure: FAR Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1)
- Set-Aside: None (sole source)
- Response Due: May 5, 2026, 11am EST
- Published: April 28, 2026
Evaluation
This is a notice of intent, not a request for quotation. A solicitation will not be issued. The government's determination not to compete the proposed requirement, based on responses to this notice, is solely at its discretion.
Additional Notes
Interested parties may identify their interest and capabilities in response to this posting. Comments should be submitted to Kristin Nagashima via email at kristin.nagashima@nih.gov.